Published: 30 October 2025
Committees
Agenda for the 75th meeting of the Medicines Classification Committee to be held via videoconference on 19 November 2025.
- Welcome
- Apologies
- Confirmation of the minutes of the 74th meeting held on 23 July 2025.
- Declaration of conflicts of interest
- Matters arising
- New medicines for classification
- Harmonisation of the New Zealand and Australian schedules
- Agenda items for the next meeting
- General business
- Date of the next meeting
1. Welcome
2. Apologies
3. Confirmation of the minutes of the 74th meeting held on 23 July 2025
4. Declaration of conflicts of interest
5. MATTERS ARISING
5.1. Objections to recommendations made at the 74th meeting
The objection period for the 74th meeting closes on 13 November 2025. Objections can be sent to committees@health.govt.nz.
6. New medicines for classification
The following new chemical entities are submitted to the Committee for classification.
New chemical entities
6.1 Relatlimab
Relatlimab is a monoclonal antibody that binds to and inhibits lymphocyte-activation gene 3 (LAG-3) receptors. In combination with nivolumab, it is indicated for the treatment of patients with unresectable or metastatic melanoma.6.2 Belantamab mafodotin
Belantamab mafodotin is an antibody-drug conjugate that contains belantamab, an afucosylated humanised monoclonal IgG1k antibody specific for B cell maturation antigen. Belantamab mafodotin is indicated for the treatment of adults with multiple myeloma.7. Harmonisation of the New Zealand and Australian schedules
Recent scheduling changes made to the Poisons Standard in Australia are to be considered by the Medicines Classification Committee for their implementation in New Zealand.
Public consultation is an important part of the Medicines Classification Committee process, stakeholders are welcome to provide comments on all agenda items including those being considered for harmonisation.
The Medsafe Medicines Classification Committee - Public Consultation on Agenda Items webpage provides information on how to comment on agenda items. There are no harmonisation matters to be discussed at the 75th Medicines Classification Committee meeting.
8. Matters arising
9. Agenda items for the next meeting
10. General business
11. Date of the next meeting
